Literature DB >> 1540020

Morphological evidence that activated polymorphs circulate in the peripheral blood of patients with rheumatoid arthritis.

D A McCarthy1, J Bernhagen, M J Taylor, A S Hamblin, I James, P W Thompson, J D Perry.   

Abstract

Purified peripheral blood polymorphonuclear leucocytes (PMNs) from patients with rheumatoid arthritis (RA) have been found to differ from purified PMNs from normal subjects in ways that are consistent with their prior activation. However, it is currently contentious whether activated PMNs really circulate in patients with RA, or whether they are produced as an in vitro artefact of purification. Recently developed rapid leucocyte fixation and preparation technique showed that the proportion of polarised (activated) PMNs (36.9 (24.7)%, mean (SD); n = 31) was increased relative to that in control subjects (8.1 (5.6)%; n = 12). Serum cytidine deaminase levels, a biochemical marker of PMN lysis, were also increased in patients with RA (11.59 (7.26) U/ml) compared with those in controls (6.82 (3.78) U/ml), but the proportion of polarised PMNs and the levels of cytidine deaminase activity were unrelated to clinical assessments of inflammatory disease activity. Twelve patients who were not receiving drugs or who were receiving only non-steroidal anti-inflammatory drugs (NSAIDs) had more polarised PMNs than 19 patients receiving second line treatment in addition to NSAIDs (patients receiving NSAIDs, 49.6 (25.9)%; patients receiving second line treatment, 27.5 (21.1)%). Fluorescence activated cytometric analysis of CR1 and CR3 expression on PMNs from a randomly selected subgroup of patients with RA showed that the serum level of cytidine deaminase activity was correlated positively with the expression of CR1 (the C3b receptor) on the cell surface and that the proportion of polarised PMNs was positively correlated with the expression of CR3 (or CD11b/CD18), the iC3b receptor that is upregulated on activation. It is suggested that the polarised PMNs which circulate in blood samples from patients with RA represent cells which have been activated but not yet marginated, or activated cells which have marginated but subsequently returned to the circulating pool.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1540020      PMCID: PMC1004610          DOI: 10.1136/ard.51.1.13

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  26 in total

1.  A rapid preparation technique for leucocytes.

Authors:  D A McCarthy; J Bernhagen; Y C Liu; J D Perry
Journal:  J Microsc       Date:  1990-04       Impact factor: 1.758

2.  Fallout from Pacific tests reaches Congress.

Authors:  E Marshall
Journal:  Science       Date:  1989-07-14       Impact factor: 47.728

3.  Distinctive functional characteristics of human "T" lymphocytes defined by E rosetting or a monoclonal anti-T cell antibody.

Authors:  P C Beverley; R E Callard
Journal:  Eur J Immunol       Date:  1981-04       Impact factor: 5.532

4.  Granulocyte-macrophage colony-stimulating factor and other cytokines regulate surface expression of the leukocyte adhesion molecule-1 on human neutrophils, monocytes, and their precursors.

Authors:  J D Griffin; O Spertini; T J Ernst; M P Belvin; H B Levine; Y Kanakura; T F Tedder
Journal:  J Immunol       Date:  1990-07-15       Impact factor: 5.422

5.  Scanning electron microscopy of rheumatoid arthritis peripheral blood polymorphonuclear leucocytes.

Authors:  D A McCarthy; C M Holburn; B K Pell; S R Moore; A P Kirk; J D Perry
Journal:  Ann Rheum Dis       Date:  1986-11       Impact factor: 19.103

6.  Interleukin 1 activity in the synovial fluid of patients with rheumatoid arthritis.

Authors:  A Fontana; H Hengartner; E Weber; K Fehr; P J Grob; G Cohen
Journal:  Rheumatol Int       Date:  1982       Impact factor: 2.631

7.  Identification of an anti-monocyte monoclonal antibody that is specific for membrane complement receptor type one (CR1).

Authors:  N Hogg; G D Ross; D B Jones; M Slusarenko; M J Walport; P J Lachmann
Journal:  Eur J Immunol       Date:  1984-03       Impact factor: 5.532

8.  Evidence for distinct intracellular pools of receptors for C3b and C3bi in human neutrophils.

Authors:  J J O'Shea; E J Brown; B E Seligmann; J A Metcalf; M M Frank; J I Gallin
Journal:  J Immunol       Date:  1985-04       Impact factor: 5.422

9.  Cytidine deaminase activity as a measure of acute inflammation in rheumatoid arthritis.

Authors:  P W Thompson; D D Jones; H L Currey
Journal:  Ann Rheum Dis       Date:  1986-01       Impact factor: 19.103

10.  The structure-activity relations of synthetic peptides as chemotactic factors and inducers of lysosomal secretion for neutrophils.

Authors:  H J Showell; R J Freer; S H Zigmond; E Schiffmann; S Aswanikumar; B Corcoran; E L Becker
Journal:  J Exp Med       Date:  1976-05-01       Impact factor: 14.307

View more
  5 in total

1.  Primed PMNs in healthy mouse and human circulation are first responders during acute inflammation.

Authors:  Noah Fine; Oriyah Barzilay; Chunxiang Sun; Nimali Wellappuli; Farzeen Tanwir; Jeffrey W Chadwick; Morvarid Oveisi; Nikola Tasevski; David Prescott; Martin Gargan; Dana J Philpott; Yigal Dror; Michael Glogauer
Journal:  Blood Adv       Date:  2019-05-28

2.  Leucocyte integrin and CR1 expression on peripheral blood leucocytes of patients with rheumatoid arthritis.

Authors:  D McCarthy; M J Taylor; J Bernhagen; J D Perry; A S Hamblin
Journal:  Ann Rheum Dis       Date:  1992-03       Impact factor: 19.103

3.  Peripheral blood neutrophil leukotriene B4 release and migration in rheumatoid arthritis.

Authors:  H Kankaanranta; E Moilanen; T Tuomiranta; M Korpela; U Yli-Kerttula; H Isomäki; H Vapaatalo
Journal:  Inflammation       Date:  1996-10       Impact factor: 4.092

4.  Tumor necrosis factor priming of peripheral blood neutrophils from rheumatoid arthritis patients.

Authors:  I C Kowanko; A Ferrante; G Clemente; P P Youssef; M Smith
Journal:  J Clin Immunol       Date:  1996-07       Impact factor: 8.317

5.  Neutrophil gelatinase levels in plasma and synovial fluid of patients with rheumatic diseases.

Authors:  I Sopata; J Wize; A Filipowicz-Sosnowska; E Stanisławska-Biernat; B Brzezińska; S Maśliński
Journal:  Rheumatol Int       Date:  1995       Impact factor: 2.631

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.